Compare AbCellera Biologics Inc (ABCL) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Tripadvisor Inc Common Stock — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Tripadvisor Inc Common Stock trades at $13.02 (market cap $1.66B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| ABCL | TRIP | |
|---|---|---|
Market Cap | $2.35B | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $19.14 |
52-Week Low | $2.78 | $9.24 |
Enterprise Value | $1.99B | $1.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TRIP trades at $13.72, down 3.99% today, with a consensus price target of $13.87. The stock shows a bullish technical trend and recently announced the $700 million sale of TheFork to American Express. Despite mixed quarterly earnings, 2025 revenue grew to $1.89 billion with a net income margin of 0.99%. Analyst sentiment is mixed, with 60.72% holding and 23.21% recommending buy.
The outlook is cautiously optimistic. The sale of TheFork provides cash but removes a growth segment. Earnings volatility and competitive pressures in online travel pose risks. Upside depends on execution in core segments and macroeconomic stability. Current valuation metrics suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
